Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2011

View Archived Issues

First-in-class agent lowers blood pressure in patients with heart failure

Final phase I data presented on Transgene hepatitis C vaccine

Helicon Therapeutics begins phase I/II trial of galanin GAL3 receptor antagonist for depression

Novel inhibitors of chemokine CCR2/CCR5 receptors described

Gilead discloses data on HCV NS3 inhibitor

Clinical data presented on doxazosin/dutasteride in men with benign prostatic hyperplasia

New anti-HIV agents prepared by GlaxoSmithKline

New inhibitors of mitogen-activated protein kinase kinase 7 claimed

Novel metabotropic glutamate mGlu4 receptor positive allosteric modulators patented

Chinese institute presents novel sodium/glucose cotransporter 2 inhibitors

Novacta Biosystems prepares novel antibacterial agents

Promising results emerge from phase IIb trial of PT-005

Preclinical program of afamelanotide for erythropoietic protoporphyria completed

Aeterna Zentaris reports encouraging phase III data on AEZS-130

Sunshine Biopharma reports on study of Adva-27a in human liver microsomes

Adamis Pharmaceuticals enrolls first patient into phase I/IIa study of APC-100

Eisai and Toyama Chemical submit MAA in Japan for iguratimod

Bionovo reports data from Menerba trial in postmenopausal women

Zymeworks and Merck & Co. to collaborate

GE Healthcare relaunches ready-to-use diagnostic ultrasound contrast agent in Europe

First patient dosed in phase I study of ZIN ATI-001

New Curemark product shows promise to treat hyperactivity

AdventRx to discuss key programs with FDA

BiondVax receives clearance for phase II Multimeric-001 study

Valeant Pharmaceuticals outlines offer to acquire Afexa Life Sciences

Pharming and Swedish Orphan Biovirum announce new Ruconest launch

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...